| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Flow Velocity | 37 | 2021 | 418 | 1.750 |
Why?
|
| Ultrasonography, Doppler | 13 | 2015 | 185 | 1.410 |
Why?
|
| Image Interpretation, Computer-Assisted | 8 | 2010 | 233 | 1.130 |
Why?
|
| Pulsatile Flow | 10 | 2011 | 110 | 0.900 |
Why?
|
| Aorta | 12 | 2021 | 521 | 0.880 |
Why?
|
| Coronary Circulation | 27 | 2009 | 188 | 0.810 |
Why?
|
| Signal Processing, Computer-Assisted | 4 | 2009 | 119 | 0.800 |
Why?
|
| Laser-Doppler Flowmetry | 3 | 2011 | 63 | 0.740 |
Why?
|
| Hemodynamics | 32 | 2011 | 806 | 0.730 |
Why?
|
| Arteries | 4 | 2011 | 210 | 0.720 |
Why?
|
| Isoflurane | 7 | 2009 | 35 | 0.690 |
Why?
|
| Coronary Vessels | 12 | 2010 | 526 | 0.690 |
Why?
|
| Carotid Arteries | 8 | 2015 | 124 | 0.660 |
Why?
|
| Vascular Resistance | 13 | 2009 | 182 | 0.640 |
Why?
|
| Aging | 14 | 2015 | 1244 | 0.610 |
Why?
|
| Transducers | 3 | 2009 | 22 | 0.590 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 3 | 2009 | 20 | 0.550 |
Why?
|
| Cardiomegaly | 5 | 2008 | 118 | 0.540 |
Why?
|
| Hemorheology | 4 | 2008 | 25 | 0.540 |
Why?
|
| Apolipoproteins E | 4 | 2009 | 187 | 0.520 |
Why?
|
| Models, Cardiovascular | 10 | 2011 | 166 | 0.520 |
Why?
|
| Echocardiography, Doppler, Pulsed | 3 | 2021 | 16 | 0.510 |
Why?
|
| Mice | 38 | 2021 | 18238 | 0.460 |
Why?
|
| Animals | 114 | 2021 | 33855 | 0.460 |
Why?
|
| Blood Pressure Determination | 3 | 2011 | 119 | 0.460 |
Why?
|
| Regional Blood Flow | 20 | 2011 | 191 | 0.410 |
Why?
|
| Myocardial Contraction | 15 | 2021 | 244 | 0.390 |
Why?
|
| Heart | 16 | 2007 | 661 | 0.390 |
Why?
|
| Ventricular Function, Left | 4 | 2021 | 550 | 0.380 |
Why?
|
| Thermography | 2 | 2009 | 12 | 0.370 |
Why?
|
| Blood Volume | 4 | 2010 | 73 | 0.360 |
Why?
|
| Vasodilator Agents | 5 | 2010 | 198 | 0.340 |
Why?
|
| Dogs | 62 | 2008 | 616 | 0.340 |
Why?
|
| Equipment Design | 7 | 2011 | 537 | 0.330 |
Why?
|
| Aortic Valve Stenosis | 2 | 2005 | 352 | 0.330 |
Why?
|
| Cardiac Catheterization | 5 | 2008 | 623 | 0.300 |
Why?
|
| Anesthetics, Inhalation | 2 | 2009 | 42 | 0.300 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2009 | 19 | 0.290 |
Why?
|
| Ventricular Function | 4 | 2008 | 83 | 0.290 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2009 | 51 | 0.290 |
Why?
|
| Coronary Disease | 18 | 2009 | 628 | 0.280 |
Why?
|
| Disease Models, Animal | 12 | 2011 | 4669 | 0.270 |
Why?
|
| Equipment Failure Analysis | 4 | 2009 | 79 | 0.260 |
Why?
|
| Mitral Valve Insufficiency | 4 | 2011 | 179 | 0.250 |
Why?
|
| Echocardiography, Three-Dimensional | 5 | 2011 | 61 | 0.240 |
Why?
|
| Mitral Valve | 5 | 2011 | 245 | 0.240 |
Why?
|
| Diastole | 8 | 2015 | 181 | 0.240 |
Why?
|
| Age Factors | 5 | 2015 | 2839 | 0.240 |
Why?
|
| Ultrasonography | 14 | 2015 | 956 | 0.230 |
Why?
|
| Myocardium | 16 | 2008 | 863 | 0.230 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2005 | 100 | 0.230 |
Why?
|
| Echocardiography, Doppler, Color | 4 | 2009 | 110 | 0.220 |
Why?
|
| Biomedical Engineering | 3 | 2009 | 21 | 0.220 |
Why?
|
| Carotid Artery Diseases | 4 | 2015 | 130 | 0.220 |
Why?
|
| Motion | 1 | 2004 | 37 | 0.220 |
Why?
|
| Hyperemia | 3 | 2009 | 31 | 0.210 |
Why?
|
| Mice, Inbred C57BL | 12 | 2021 | 4714 | 0.210 |
Why?
|
| Echocardiography, Doppler | 3 | 2001 | 160 | 0.200 |
Why?
|
| Blood Pressure | 23 | 2011 | 1343 | 0.190 |
Why?
|
| Systole | 10 | 2008 | 195 | 0.190 |
Why?
|
| Vascular Stiffness | 2 | 2015 | 82 | 0.190 |
Why?
|
| Surgical Flaps | 4 | 2010 | 179 | 0.180 |
Why?
|
| Arteriosclerosis | 2 | 2000 | 110 | 0.180 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2002 | 28 | 0.180 |
Why?
|
| Atherosclerosis | 1 | 2010 | 951 | 0.180 |
Why?
|
| Vasodilation | 7 | 2010 | 175 | 0.180 |
Why?
|
| Monitoring, Physiologic | 3 | 2002 | 369 | 0.170 |
Why?
|
| Myocardial Reperfusion | 7 | 2008 | 53 | 0.170 |
Why?
|
| Aorta, Thoracic | 2 | 1997 | 527 | 0.170 |
Why?
|
| Reproducibility of Results | 7 | 2013 | 2908 | 0.170 |
Why?
|
| Cardiovascular Diseases | 2 | 2011 | 2105 | 0.170 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 2 | 2011 | 37 | 0.160 |
Why?
|
| Mice, Knockout | 7 | 2011 | 3834 | 0.160 |
Why?
|
| Echocardiography | 7 | 2011 | 1127 | 0.160 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 2105 | 0.150 |
Why?
|
| Muscle, Smooth, Vascular | 4 | 2011 | 225 | 0.150 |
Why?
|
| Tantalum | 1 | 1999 | 8 | 0.150 |
Why?
|
| Radioisotopes | 1 | 1999 | 26 | 0.150 |
Why?
|
| Nitric Oxide | 4 | 2010 | 466 | 0.140 |
Why?
|
| Myocardial Ischemia | 5 | 2008 | 308 | 0.140 |
Why?
|
| Fingers | 2 | 2009 | 63 | 0.140 |
Why?
|
| Heart Rate | 21 | 2002 | 576 | 0.140 |
Why?
|
| Ultrasonics | 6 | 2000 | 31 | 0.140 |
Why?
|
| Anesthetics | 3 | 2008 | 77 | 0.140 |
Why?
|
| Pulse | 1 | 1997 | 28 | 0.130 |
Why?
|
| Hypertension | 4 | 2013 | 1349 | 0.130 |
Why?
|
| Mice, Mutant Strains | 3 | 2013 | 358 | 0.130 |
Why?
|
| Manometry | 1 | 1997 | 73 | 0.130 |
Why?
|
| Aorta, Abdominal | 1 | 1997 | 95 | 0.130 |
Why?
|
| Electrocardiography | 7 | 2009 | 973 | 0.130 |
Why?
|
| omega-N-Methylarginine | 5 | 2008 | 10 | 0.120 |
Why?
|
| Heart Atria | 3 | 2015 | 335 | 0.120 |
Why?
|
| Transducers, Pressure | 3 | 2011 | 10 | 0.120 |
Why?
|
| Algorithms | 4 | 2011 | 1678 | 0.120 |
Why?
|
| Heart Failure, Diastolic | 1 | 2015 | 10 | 0.120 |
Why?
|
| Liver | 13 | 1998 | 1793 | 0.110 |
Why?
|
| Atrial Function, Left | 1 | 2015 | 35 | 0.110 |
Why?
|
| Pulmonary Artery | 2 | 2015 | 438 | 0.110 |
Why?
|
| Postprandial Period | 1 | 2015 | 87 | 0.110 |
Why?
|
| Energy Intake | 1 | 1997 | 498 | 0.110 |
Why?
|
| Vasoconstriction | 4 | 2011 | 94 | 0.100 |
Why?
|
| Dietary Fats | 1 | 2015 | 275 | 0.100 |
Why?
|
| Insulin | 12 | 1998 | 1140 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 188 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2013 | 321 | 0.100 |
Why?
|
| Aging, Premature | 1 | 2013 | 31 | 0.100 |
Why?
|
| Shock, Septic | 2 | 2008 | 148 | 0.100 |
Why?
|
| Anastomosis, Surgical | 2 | 2010 | 176 | 0.100 |
Why?
|
| Growth Hormone | 1 | 2013 | 129 | 0.100 |
Why?
|
| Fourier Analysis | 2 | 2008 | 54 | 0.100 |
Why?
|
| Cardiac Pacing, Artificial | 3 | 2004 | 132 | 0.100 |
Why?
|
| Albumins | 1 | 1993 | 87 | 0.090 |
Why?
|
| Heart Function Tests | 2 | 2009 | 50 | 0.090 |
Why?
|
| Liver Circulation | 7 | 1992 | 19 | 0.090 |
Why?
|
| Potassium | 3 | 2010 | 268 | 0.090 |
Why?
|
| Miniaturization | 1 | 2011 | 26 | 0.090 |
Why?
|
| Laser Therapy | 1 | 1994 | 241 | 0.090 |
Why?
|
| Carotid Artery, Common | 1 | 2011 | 59 | 0.090 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2005 | 198 | 0.080 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 156 | 0.080 |
Why?
|
| Computer Systems | 2 | 2009 | 35 | 0.080 |
Why?
|
| Artificial Intelligence | 2 | 2005 | 354 | 0.080 |
Why?
|
| Veins | 1 | 2010 | 95 | 0.080 |
Why?
|
| Basilar Artery | 1 | 2010 | 18 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2010 | 812 | 0.080 |
Why?
|
| Male | 43 | 2021 | 64498 | 0.080 |
Why?
|
| Tachycardia | 1 | 1990 | 70 | 0.080 |
Why?
|
| Myocardial Infarction | 4 | 2002 | 1001 | 0.080 |
Why?
|
| Hydrops Fetalis | 1 | 1990 | 83 | 0.080 |
Why?
|
| Muscles | 3 | 1994 | 203 | 0.080 |
Why?
|
| Skin Temperature | 1 | 2009 | 17 | 0.070 |
Why?
|
| Contrast Media | 1 | 1993 | 482 | 0.070 |
Why?
|
| Blood Glucose | 10 | 1998 | 1110 | 0.070 |
Why?
|
| Models, Animal | 2 | 2008 | 451 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2011 | 371 | 0.070 |
Why?
|
| Middle Cerebral Artery | 1 | 2010 | 118 | 0.070 |
Why?
|
| Hydralazine | 2 | 2001 | 8 | 0.070 |
Why?
|
| Glucose | 7 | 1998 | 853 | 0.070 |
Why?
|
| Cardiac Output | 9 | 2001 | 152 | 0.070 |
Why?
|
| Myocardial Reperfusion Injury | 4 | 2001 | 129 | 0.070 |
Why?
|
| Coronary Stenosis | 1 | 2009 | 78 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2008 | 91 | 0.070 |
Why?
|
| Heart Ventricles | 5 | 2008 | 762 | 0.070 |
Why?
|
| Dobutamine | 3 | 2021 | 51 | 0.070 |
Why?
|
| Antihypertensive Agents | 2 | 2001 | 419 | 0.070 |
Why?
|
| Humans | 34 | 2015 | 130496 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2008 | 185 | 0.070 |
Why?
|
| Muscle, Smooth | 2 | 2004 | 114 | 0.060 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2009 | 147 | 0.060 |
Why?
|
| Enzyme Inhibitors | 4 | 2008 | 562 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 243 | 0.060 |
Why?
|
| Species Specificity | 1 | 2008 | 477 | 0.060 |
Why?
|
| Lipopolysaccharides | 1 | 2008 | 301 | 0.060 |
Why?
|
| Cerebrovascular Circulation | 1 | 2010 | 484 | 0.060 |
Why?
|
| Female | 37 | 2021 | 70401 | 0.060 |
Why?
|
| Guanidines | 2 | 2008 | 21 | 0.060 |
Why?
|
| Aortic Valve | 2 | 2008 | 454 | 0.060 |
Why?
|
| Swine | 4 | 2008 | 1185 | 0.060 |
Why?
|
| Glucagon | 7 | 1998 | 146 | 0.060 |
Why?
|
| Body Temperature | 2 | 2004 | 126 | 0.060 |
Why?
|
| Isoproterenol | 6 | 2001 | 88 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2006 | 89 | 0.060 |
Why?
|
| Constriction | 2 | 2003 | 46 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2008 | 362 | 0.050 |
Why?
|
| Phenotype | 4 | 2013 | 4479 | 0.050 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2004 | 72 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 892 | 0.050 |
Why?
|
| Alternative Splicing | 1 | 2005 | 312 | 0.050 |
Why?
|
| Tail | 1 | 2003 | 11 | 0.050 |
Why?
|
| Microcirculation | 2 | 1993 | 107 | 0.050 |
Why?
|
| Time Factors | 8 | 2015 | 6206 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1438 | 0.050 |
Why?
|
| Anesthetics, Intravenous | 1 | 2002 | 48 | 0.050 |
Why?
|
| Actins | 1 | 2004 | 315 | 0.050 |
Why?
|
| Propofol | 1 | 2002 | 49 | 0.050 |
Why?
|
| Verapamil | 3 | 1989 | 47 | 0.050 |
Why?
|
| Ethylamines | 1 | 2001 | 1 | 0.040 |
Why?
|
| Organoselenium Compounds | 1 | 2001 | 5 | 0.040 |
Why?
|
| Portal Vein | 4 | 1998 | 85 | 0.040 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2002 | 81 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2009 | 890 | 0.040 |
Why?
|
| Renal Circulation | 4 | 1991 | 41 | 0.040 |
Why?
|
| Heparin Antagonists | 1 | 2001 | 4 | 0.040 |
Why?
|
| Protamines | 1 | 2001 | 12 | 0.040 |
Why?
|
| Enflurane | 3 | 1992 | 3 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 2300 | 0.040 |
Why?
|
| Body Weight | 2 | 2007 | 987 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2005 | 539 | 0.040 |
Why?
|
| Free Radicals | 4 | 1995 | 35 | 0.040 |
Why?
|
| Hepatic Artery | 3 | 1998 | 45 | 0.040 |
Why?
|
| Ventricular Pressure | 1 | 2021 | 36 | 0.040 |
Why?
|
| Elasticity | 3 | 2006 | 94 | 0.040 |
Why?
|
| Acceleration | 1 | 2021 | 26 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 4 | 2002 | 169 | 0.040 |
Why?
|
| Thallium | 1 | 2000 | 6 | 0.040 |
Why?
|
| Phenethylamines | 1 | 2000 | 16 | 0.040 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2000 | 24 | 0.040 |
Why?
|
| Propranolol | 4 | 1996 | 111 | 0.040 |
Why?
|
| Hematocrit | 1 | 2000 | 104 | 0.040 |
Why?
|
| Ophthalmic Artery | 1 | 1980 | 16 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2001 | 544 | 0.040 |
Why?
|
| Desmin | 1 | 1999 | 19 | 0.040 |
Why?
|
| Heparin | 1 | 2001 | 203 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 2 | 2011 | 138 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2001 | 243 | 0.040 |
Why?
|
| Anesthesia | 2 | 2002 | 210 | 0.040 |
Why?
|
| Adenosine | 1 | 2000 | 119 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2000 | 162 | 0.040 |
Why?
|
| Organ Size | 1 | 2000 | 412 | 0.040 |
Why?
|
| Orbit | 1 | 1980 | 75 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2001 | 212 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 1994 | 808 | 0.040 |
Why?
|
| Gamma Cameras | 1 | 1999 | 3 | 0.040 |
Why?
|
| Radionuclide Ventriculography | 1 | 1999 | 4 | 0.040 |
Why?
|
| Heart Failure | 4 | 2002 | 2335 | 0.040 |
Why?
|
| Rats | 4 | 2001 | 3380 | 0.040 |
Why?
|
| Regeneration | 1 | 2001 | 227 | 0.040 |
Why?
|
| Ventricular Remodeling | 1 | 1999 | 154 | 0.040 |
Why?
|
| Splanchnic Circulation | 1 | 1998 | 49 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2001 | 469 | 0.030 |
Why?
|
| Myocardial Stunning | 2 | 1995 | 18 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1990 | 181 | 0.030 |
Why?
|
| Stroke Volume | 3 | 1999 | 542 | 0.030 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 1999 | 161 | 0.030 |
Why?
|
| Cholesterol | 1 | 2000 | 538 | 0.030 |
Why?
|
| Prostaglandins | 2 | 1990 | 34 | 0.030 |
Why?
|
| Octreotide | 1 | 1997 | 24 | 0.030 |
Why?
|
| Observer Variation | 2 | 2008 | 309 | 0.030 |
Why?
|
| Cardiomyoplasty | 1 | 1996 | 4 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2001 | 600 | 0.030 |
Why?
|
| Hyperthyroidism | 1 | 1996 | 24 | 0.030 |
Why?
|
| Stem Cells | 1 | 2001 | 711 | 0.030 |
Why?
|
| Angiotensin II | 2 | 1988 | 130 | 0.030 |
Why?
|
| Mammals | 1 | 1997 | 253 | 0.030 |
Why?
|
| Middle Aged | 8 | 2013 | 28448 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1997 | 760 | 0.030 |
Why?
|
| Pulse Wave Analysis | 1 | 2015 | 52 | 0.030 |
Why?
|
| Lasalocid | 3 | 1982 | 3 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 1993 | 236 | 0.030 |
Why?
|
| Ligation | 3 | 2003 | 131 | 0.030 |
Why?
|
| Vitamin E | 1 | 1995 | 63 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 151 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2001 | 1000 | 0.030 |
Why?
|
| Halothane | 2 | 2001 | 7 | 0.030 |
Why?
|
| Cattle | 2 | 1994 | 502 | 0.030 |
Why?
|
| Assisted Circulation | 1 | 1994 | 23 | 0.030 |
Why?
|
| Vena Cava, Superior | 1 | 1995 | 58 | 0.030 |
Why?
|
| Organ Specificity | 2 | 2008 | 397 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 1610 | 0.030 |
Why?
|
| Mice, Transgenic | 3 | 2005 | 2336 | 0.030 |
Why?
|
| Electric Stimulation Therapy | 1 | 1994 | 88 | 0.020 |
Why?
|
| Exercise Test | 2 | 2007 | 237 | 0.020 |
Why?
|
| Adult | 7 | 2015 | 31183 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2015 | 1450 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 2 | 1993 | 1156 | 0.020 |
Why?
|
| Muscle Contraction | 1 | 1993 | 146 | 0.020 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2013 | 77 | 0.020 |
Why?
|
| Catheterization | 1 | 1974 | 223 | 0.020 |
Why?
|
| Microspheres | 1 | 1993 | 67 | 0.020 |
Why?
|
| Reference Values | 2 | 1991 | 680 | 0.020 |
Why?
|
| Ethers | 1 | 1992 | 8 | 0.020 |
Why?
|
| Methyl Ethers | 1 | 1992 | 23 | 0.020 |
Why?
|
| Homeostasis | 1 | 1997 | 715 | 0.020 |
Why?
|
| Catalase | 2 | 1990 | 63 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2001 | 1267 | 0.020 |
Why?
|
| Arterial Pressure | 1 | 2013 | 131 | 0.020 |
Why?
|
| Hypotension | 2 | 2008 | 183 | 0.020 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2011 | 5 | 0.020 |
Why?
|
| Drug Interactions | 4 | 2001 | 236 | 0.020 |
Why?
|
| Calcium Channel Agonists | 1 | 2011 | 11 | 0.020 |
Why?
|
| Postoperative Period | 2 | 2009 | 330 | 0.020 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2011 | 33 | 0.020 |
Why?
|
| Potassium Chloride | 1 | 2011 | 45 | 0.020 |
Why?
|
| Superoxide Dismutase | 2 | 1990 | 176 | 0.020 |
Why?
|
| Antioxidants | 1 | 1994 | 335 | 0.020 |
Why?
|
| Endocardium | 2 | 2008 | 46 | 0.020 |
Why?
|
| rho-Associated Kinases | 1 | 2011 | 48 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 1994 | 521 | 0.020 |
Why?
|
| Sex Factors | 2 | 2005 | 1343 | 0.020 |
Why?
|
| Electromagnetic Phenomena | 1 | 1990 | 4 | 0.020 |
Why?
|
| Nitroglycerin | 1 | 1990 | 23 | 0.020 |
Why?
|
| Lymph | 1 | 1990 | 7 | 0.020 |
Why?
|
| Thromboxane B2 | 1 | 1990 | 17 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2011 | 292 | 0.020 |
Why?
|
| alpha-Linolenic Acid | 1 | 2010 | 15 | 0.020 |
Why?
|
| Autonomic Nervous System | 1 | 1990 | 48 | 0.020 |
Why?
|
| Mammaplasty | 1 | 2010 | 44 | 0.020 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2010 | 22 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2010 | 63 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2010 | 52 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1990 | 45 | 0.020 |
Why?
|
| Thiopental | 1 | 1989 | 3 | 0.020 |
Why?
|
| Cardiotonic Agents | 2 | 2001 | 139 | 0.020 |
Why?
|
| Mice, Inbred Strains | 2 | 2003 | 263 | 0.020 |
Why?
|
| Potassium Channel Blockers | 1 | 2010 | 84 | 0.020 |
Why?
|
| Sheep | 1 | 1990 | 219 | 0.020 |
Why?
|
| Ventricular Fibrillation | 1 | 1990 | 53 | 0.020 |
Why?
|
| Ascites | 1 | 1990 | 98 | 0.020 |
Why?
|
| Mitochondria, Heart | 2 | 1981 | 60 | 0.020 |
Why?
|
| Blood Proteins | 1 | 1990 | 140 | 0.020 |
Why?
|
| Edema | 1 | 1990 | 134 | 0.020 |
Why?
|
| Phentolamine | 1 | 1988 | 15 | 0.020 |
Why?
|
| Acid-Base Equilibrium | 1 | 1988 | 60 | 0.020 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2010 | 171 | 0.020 |
Why?
|
| Atropine | 2 | 1985 | 29 | 0.020 |
Why?
|
| Propanolamines | 1 | 2008 | 18 | 0.020 |
Why?
|
| Young Adult | 2 | 2015 | 10010 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2009 | 3110 | 0.020 |
Why?
|
| Deferoxamine | 1 | 1987 | 7 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 1988 | 199 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2009 | 144 | 0.020 |
Why?
|
| Pyrazolones | 1 | 1987 | 2 | 0.020 |
Why?
|
| Lipoxygenase | 1 | 1987 | 3 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2008 | 211 | 0.020 |
Why?
|
| Thiourea | 1 | 1987 | 9 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 6812 | 0.020 |
Why?
|
| Acidosis | 1 | 1988 | 97 | 0.020 |
Why?
|
| Adrenergic beta-Agonists | 2 | 1985 | 79 | 0.020 |
Why?
|
| Nicardipine | 1 | 1987 | 15 | 0.020 |
Why?
|
| Action Potentials | 1 | 2010 | 470 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 578 | 0.020 |
Why?
|
| Tiopronin | 1 | 1986 | 2 | 0.020 |
Why?
|
| Dwarfism | 1 | 2007 | 104 | 0.020 |
Why?
|
| Amino Acids, Sulfur | 1 | 1986 | 15 | 0.020 |
Why?
|
| Pancreatectomy | 2 | 1984 | 146 | 0.020 |
Why?
|
| Pressoreceptors | 1 | 1986 | 9 | 0.020 |
Why?
|
| Angioplasty, Balloon | 1 | 1987 | 123 | 0.020 |
Why?
|
| Kinetics | 5 | 1987 | 1087 | 0.020 |
Why?
|
| Reflex | 1 | 1986 | 35 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2006 | 34 | 0.010 |
Why?
|
| Pericardium | 1 | 1986 | 103 | 0.010 |
Why?
|
| CELF Proteins | 1 | 2005 | 7 | 0.010 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 1985 | 19 | 0.010 |
Why?
|
| Rheology | 1 | 1985 | 24 | 0.010 |
Why?
|
| Aged | 4 | 2009 | 20928 | 0.010 |
Why?
|
| Linear Models | 1 | 2007 | 687 | 0.010 |
Why?
|
| Cardiomyopathies | 2 | 2008 | 519 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1986 | 250 | 0.010 |
Why?
|
| Chlorisondamine | 3 | 1990 | 3 | 0.010 |
Why?
|
| Penetrance | 1 | 2005 | 109 | 0.010 |
Why?
|
| Renin | 1 | 1985 | 75 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2010 | 633 | 0.010 |
Why?
|
| Pyrazoles | 1 | 1987 | 357 | 0.010 |
Why?
|
| Thrombosis | 1 | 2009 | 493 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 1985 | 223 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 591 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 2596 | 0.010 |
Why?
|
| Pancreatic Polypeptide | 1 | 1983 | 5 | 0.010 |
Why?
|
| Mathematics | 1 | 1983 | 71 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 2004 | 237 | 0.010 |
Why?
|
| Multivariate Analysis | 2 | 2002 | 1377 | 0.010 |
Why?
|
| Consciousness | 4 | 1989 | 56 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2005 | 654 | 0.010 |
Why?
|
| Heart Conduction System | 1 | 2004 | 161 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2005 | 521 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2006 | 673 | 0.010 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1984 | 140 | 0.010 |
Why?
|
| Research Design | 1 | 2007 | 715 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2005 | 565 | 0.010 |
Why?
|
| Solvents | 1 | 2002 | 40 | 0.010 |
Why?
|
| Captopril | 1 | 2002 | 23 | 0.010 |
Why?
|
| Oxygen | 1 | 1985 | 551 | 0.010 |
Why?
|
| Acute Disease | 2 | 1996 | 1149 | 0.010 |
Why?
|
| Heart Septum | 1 | 2002 | 44 | 0.010 |
Why?
|
| Tolbutamide | 1 | 1981 | 5 | 0.010 |
Why?
|
| Dopamine | 2 | 1981 | 254 | 0.010 |
Why?
|
| Rats, Inbred SHR | 1 | 2001 | 52 | 0.010 |
Why?
|
| Radiation Chimera | 1 | 2001 | 16 | 0.010 |
Why?
|
| Dietary Proteins | 1 | 1983 | 221 | 0.010 |
Why?
|
| Cell Transplantation | 1 | 2001 | 37 | 0.010 |
Why?
|
| Cardiology | 1 | 1986 | 509 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2001 | 135 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 2 | 1986 | 227 | 0.010 |
Why?
|
| Acetylcholine | 1 | 2001 | 73 | 0.010 |
Why?
|
| Muscle Development | 1 | 2001 | 73 | 0.010 |
Why?
|
| Purinergic P1 Receptor Agonists | 1 | 2000 | 6 | 0.010 |
Why?
|
| Heart Arrest, Induced | 1 | 1981 | 74 | 0.010 |
Why?
|
| Doppler Effect | 1 | 1980 | 2 | 0.010 |
Why?
|
| Intraoperative Period | 2 | 1990 | 63 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 217 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 3041 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2001 | 301 | 0.010 |
Why?
|
| Brain | 2 | 1990 | 3165 | 0.010 |
Why?
|
| Hepatic Veins | 3 | 1985 | 20 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2001 | 195 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 725 | 0.010 |
Why?
|
| Administration, Oral | 3 | 1987 | 708 | 0.010 |
Why?
|
| Carotid Artery, Internal | 1 | 1980 | 55 | 0.010 |
Why?
|
| Chimera | 1 | 1999 | 80 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 3680 | 0.010 |
Why?
|
| Catecholamines | 1 | 1979 | 50 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2001 | 231 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2001 | 343 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2001 | 319 | 0.010 |
Why?
|
| Palmitoyl Coenzyme A | 1 | 1979 | 1 | 0.010 |
Why?
|
| Phosphorylase b | 1 | 1979 | 3 | 0.010 |
Why?
|
| Palmitoylcarnitine | 1 | 1979 | 4 | 0.010 |
Why?
|
| Phosphorylases | 1 | 1979 | 7 | 0.010 |
Why?
|
| Graft Survival | 1 | 2001 | 459 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2001 | 938 | 0.010 |
Why?
|
| Acyl Coenzyme A | 1 | 1979 | 23 | 0.010 |
Why?
|
| Glycogen | 1 | 1979 | 51 | 0.010 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 1979 | 26 | 0.010 |
Why?
|
| Glutamates | 1 | 1979 | 51 | 0.010 |
Why?
|
| Acyltransferases | 1 | 1979 | 62 | 0.010 |
Why?
|
| Models, Biological | 1 | 1983 | 1386 | 0.010 |
Why?
|
| Carnitine | 1 | 1979 | 70 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2001 | 589 | 0.010 |
Why?
|
| Methods | 1 | 1978 | 95 | 0.010 |
Why?
|
| Injections, Intraventricular | 2 | 1990 | 53 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2008 | 6451 | 0.010 |
Why?
|
| Calibration | 1 | 1978 | 94 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 1601 | 0.010 |
Why?
|
| Kidney | 3 | 1982 | 1278 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 2 | 1994 | 484 | 0.010 |
Why?
|
| Liver Glycogen | 1 | 1997 | 22 | 0.010 |
Why?
|
| Indomethacin | 2 | 1990 | 78 | 0.010 |
Why?
|
| Adolescent | 2 | 2009 | 20739 | 0.010 |
Why?
|
| Survival Rate | 1 | 2002 | 2127 | 0.010 |
Why?
|
| Coronary Artery Bypass | 2 | 1990 | 515 | 0.010 |
Why?
|
| Corrosion Casting | 1 | 1995 | 2 | 0.010 |
Why?
|
| Tetrazolium Salts | 1 | 1995 | 10 | 0.010 |
Why?
|
| Thyroxine | 1 | 1996 | 58 | 0.010 |
Why?
|
| Coloring Agents | 1 | 1995 | 70 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2001 | 2903 | 0.010 |
Why?
|
| Nitrogen Oxides | 1 | 1995 | 5 | 0.010 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 1995 | 18 | 0.010 |
Why?
|
| Cyclic N-Oxides | 1 | 1995 | 19 | 0.010 |
Why?
|
| Infusions, Parenteral | 2 | 1985 | 78 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 2 | 1985 | 127 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1979 | 504 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 2 | 1978 | 2564 | 0.010 |
Why?
|
| Risk Factors | 1 | 2009 | 10959 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1978 | 491 | 0.010 |
Why?
|
| Back | 1 | 1993 | 12 | 0.010 |
Why?
|
| Angiography | 1 | 1974 | 181 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2001 | 1928 | 0.010 |
Why?
|
| Cell Death | 1 | 1994 | 233 | 0.010 |
Why?
|
| Nitrous Oxide | 1 | 1992 | 12 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 1986 | 150 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1996 | 1236 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 1974 | 453 | 0.010 |
Why?
|
| Angina, Unstable | 1 | 1991 | 49 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1999 | 2345 | 0.010 |
Why?
|
| Calcium | 1 | 1996 | 1028 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1991 | 163 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 1995 | 796 | 0.000 |
Why?
|
| Decalcification Technique | 1 | 1969 | 2 | 0.000 |
Why?
|
| Depression, Chemical | 1 | 1989 | 33 | 0.000 |
Why?
|
| Edetic Acid | 1 | 1969 | 25 | 0.000 |
Why?
|
| Iliac Artery | 1 | 1969 | 63 | 0.000 |
Why?
|
| Cadaver | 1 | 1969 | 118 | 0.000 |
Why?
|
| Reaction Time | 1 | 1990 | 156 | 0.000 |
Why?
|
| Partial Pressure | 1 | 1988 | 27 | 0.000 |
Why?
|
| Oxygen Consumption | 2 | 1981 | 298 | 0.000 |
Why?
|
| Receptors, Adrenergic | 1 | 1988 | 15 | 0.000 |
Why?
|
| Biomechanical Phenomena | 1 | 1990 | 271 | 0.000 |
Why?
|
| Receptors, Vasopressin | 1 | 1988 | 13 | 0.000 |
Why?
|
| Arginine Vasopressin | 1 | 1988 | 25 | 0.000 |
Why?
|
| Adaptation, Physiological | 1 | 1990 | 259 | 0.000 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 1987 | 3 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1988 | 411 | 0.000 |
Why?
|
| Dilatation, Pathologic | 1 | 1987 | 76 | 0.000 |
Why?
|
| Epinephrine | 1 | 1988 | 150 | 0.000 |
Why?
|
| Radiography | 1 | 1969 | 742 | 0.000 |
Why?
|
| Carbon Dioxide | 1 | 1988 | 273 | 0.000 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 1988 | 140 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1987 | 248 | 0.000 |
Why?
|
| Femoral Artery | 1 | 1986 | 134 | 0.000 |
Why?
|
| Sulfates | 1 | 1985 | 32 | 0.000 |
Why?
|
| Receptor, Insulin | 1 | 1985 | 63 | 0.000 |
Why?
|
| Diatrizoate Meglumine | 1 | 1985 | 16 | 0.000 |
Why?
|
| Dipyridamole | 1 | 1985 | 20 | 0.000 |
Why?
|
| Neutrophils | 1 | 1987 | 361 | 0.000 |
Why?
|
| Infusions, Intravenous | 1 | 1986 | 535 | 0.000 |
Why?
|
| Adenosine Triphosphate | 1 | 1985 | 266 | 0.000 |
Why?
|
| Portal System | 1 | 1984 | 35 | 0.000 |
Why?
|
| Iron | 1 | 1987 | 305 | 0.000 |
Why?
|
| Perfusion | 1 | 1985 | 211 | 0.000 |
Why?
|
| Wakefulness | 1 | 1985 | 103 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1985 | 450 | 0.000 |
Why?
|
| Meat | 1 | 1983 | 44 | 0.000 |
Why?
|
| Anesthesia, General | 1 | 1983 | 142 | 0.000 |
Why?
|
| Nitroprusside | 1 | 1981 | 35 | 0.000 |
Why?
|
| Eating | 1 | 1983 | 378 | 0.000 |
Why?
|
| Arginine | 1 | 1983 | 337 | 0.000 |
Why?
|
| Compliance | 1 | 1979 | 18 | 0.000 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1979 | 18 | 0.000 |
Why?
|
| Blood Circulation | 1 | 1979 | 14 | 0.000 |
Why?
|
| Papillary Muscles | 1 | 1979 | 19 | 0.000 |
Why?
|
| Citric Acid Cycle | 1 | 1979 | 44 | 0.000 |
Why?
|
| Cardiopulmonary Bypass | 1 | 1981 | 359 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1981 | 1168 | 0.000 |
Why?
|
| Oxidation-Reduction | 1 | 1979 | 434 | 0.000 |
Why?
|
| Energy Metabolism | 1 | 1981 | 800 | 0.000 |
Why?
|
| Animals, Newborn | 1 | 1979 | 1015 | 0.000 |
Why?
|
| Stimulation, Chemical | 1 | 1975 | 43 | 0.000 |
Why?
|
| Cell Membrane Permeability | 1 | 1975 | 66 | 0.000 |
Why?
|
| Norepinephrine | 1 | 1975 | 150 | 0.000 |
Why?
|
| Shock, Hemorrhagic | 1 | 1975 | 51 | 0.000 |
Why?
|